Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives

What's Making Shorts Go Long

Inside Wall Street


Guilford Securities, an investment firm in Chicago, is known in the business as "a den of the shorts." Usually, "we take just one long buy position a year," says Mitch Kopin, a portfolio strategist at Guilford. So investors pay attention when the Guilford pros go bullish on a stock.

A "must-buy," says Kopin, is STAAR Surgical, which has "an almost exclusive right" to a $500 million market: the just-emerging "foldable" intraocular lens business. Here's why.

In September, the Food & Drug Administration granted a patent for STAAR's foldable lens, which analysts predict will be used in about 90% of all cataract surgeries. What's appealing about the lens? It requires only a tiny 3.5 millimeter incision for surgeons to insert it in the eye of cataract patients. The procedure using a hard lens requires an incision of 5mm to 11mm.

STAAR has licensed its big competitors--Cooper Cos., Allergan, and Chiron-- to distribute the foldable lens in return for a royalty fee of 6% of net revenues. But it is preparing to go into making the lens, which is the more lucrative side of the business. The market for the new lens is expected to grow by 15% to 20% a year. Kopin figures STAAR will be in the black in 1992, after an expected loss in 1991. And in 1993, he sees a net of $1 a share. He thinks the stock, now at 7, will double by early 1993.BY GENE G. MARCIAL

blog comments powered by Disqus